Last reviewed · How we verify
LW402
LW402 is a small molecule that targets the SGLT2 receptor.
LW402 is a small molecule that targets the SGLT2 receptor. Used for Type 2 diabetes.
At a glance
| Generic name | LW402 |
|---|---|
| Sponsor | Shanghai Longwood Biopharmaceuticals Co., Ltd. |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
By inhibiting SGLT2, LW402 reduces glucose reabsorption in the kidneys, lowering blood glucose levels. This makes it a potential treatment for type 2 diabetes.
Approved indications
- Type 2 diabetes
Common side effects
- Increased risk of genital yeast infections
Key clinical trials
- Evaluation of the Efficacy and Safety of Oral LW402 Tablets for the Treatment of Patients With Moderate-to-Severe Atopic Dermatitis (PHASE3)
- Study of LW402 Tablets in Moderate to Severe Rheumatoid Arthritis (PHASE2)
- Study of LW402 in Moderate-to-Severe Atopic Dermatitis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |